Johnson & Johnson (NYSE:JNJ) Stock Holdings Boosted by Oppenheimer Asset Management Inc.

Posted by on Aug 27th, 2023

Oppenheimer Asset Management Inc. increased its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 3.6% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 534,648 shares of the company’s stock after buying an additional 18,358 shares during the quarter. Johnson & Johnson comprises about 1.3% of Oppenheimer Asset Management Inc.’s holdings, making the stock its 6th largest position. Oppenheimer Asset Management Inc.’s holdings in Johnson & Johnson were worth $82,870,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. GW&K Investment Management LLC purchased a new stake in Johnson & Johnson in the 4th quarter valued at approximately $35,000. Dark Forest Capital Management LP boosted its holdings in Johnson & Johnson by 1,044.4% in the 4th quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock valued at $36,000 after purchasing an additional 188 shares in the last quarter. Ruedi Wealth Management Inc. purchased a new stake in Johnson & Johnson in the 4th quarter valued at approximately $42,000. Kepos Capital LP purchased a new stake in Johnson & Johnson in the 4th quarter valued at approximately $45,000. Finally, 25 LLC purchased a new stake in Johnson & Johnson in the 1st quarter valued at approximately $55,000. Hedge funds and other institutional investors own 67.57% of the company’s stock.

Johnson & Johnson Trading Up 1.4 %

Shares of JNJ opened at $166.25 on Friday. The stock has a fifty day moving average of $166.68 and a two-hundred day moving average of $161.48. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.88 and a current ratio of 1.12. The company has a market capitalization of $432.08 billion, a PE ratio of 33.65, a price-to-earnings-growth ratio of 2.77 and a beta of 0.54. Johnson & Johnson has a fifty-two week low of $150.11 and a fifty-two week high of $181.04.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its quarterly earnings results on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, beating the consensus estimate of $2.62 by $0.18. The company had revenue of $25.53 billion during the quarter, compared to the consensus estimate of $24.63 billion. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. Johnson & Johnson’s revenue was up 6.3% on a year-over-year basis. During the same period in the previous year, the firm posted $2.59 EPS. As a group, analysts forecast that Johnson & Johnson will post 10.75 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 7th. Stockholders of record on Monday, August 28th will be paid a dividend of $1.19 per share. The ex-dividend date is Friday, August 25th. This represents a $4.76 annualized dividend and a dividend yield of 2.86%. Johnson & Johnson’s dividend payout ratio is presently 96.36%.

Insider Activity

In other news, EVP Kathryn E. Wengel sold 12,465 shares of the business’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the completion of the sale, the executive vice president now directly owns 65,934 shares of the company’s stock, valued at approximately $10,549,440. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, VP Peter Fasolo sold 20,000 shares of the business’s stock in a transaction on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the completion of the sale, the vice president now directly owns 102,696 shares of the company’s stock, valued at approximately $17,491,182.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Kathryn E. Wengel sold 12,465 shares of the company’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the sale, the executive vice president now directly owns 65,934 shares of the company’s stock, valued at $10,549,440. The disclosure for this sale can be found here. Insiders sold 47,163 shares of company stock valued at $7,928,856 in the last ninety days. Company insiders own 0.20% of the company’s stock.

Analyst Ratings Changes

JNJ has been the topic of a number of analyst reports. StockNews.com initiated coverage on Johnson & Johnson in a report on Thursday, August 17th. They issued a “strong-buy” rating on the stock. Atlantic Securities lifted their price target on shares of Johnson & Johnson from $167.00 to $170.00 and gave the company a “neutral” rating in a research report on Friday, August 4th. Credit Suisse Group lifted their price target on shares of Johnson & Johnson from $170.00 to $175.00 and gave the company a “neutral” rating in a research report on Friday, July 21st. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Tuesday, August 22nd. Finally, TheStreet upgraded shares of Johnson & Johnson from a “c+” rating to a “b+” rating in a research report on Monday, August 21st. Eight research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $171.80.

Get Our Latest Stock Report on Johnson & Johnson

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.